QT
AVDL

Quantbot Technologies’s Avadel Pharmaceuticals AVDL Stock Holding History

Quantbot Technologies’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79,909
Closed -$1.72M – 1708
2025
Q4 		$1.72M Buy
79,909
+31,619
+65% +$614K 0.06% 501
2025
Q3 		$737K Buy
+48,290
New +$628K 0.02% 877
2024
Q3 		– Sell
-9,733
Closed -$137K – 1441
2024
Q2 		$137K Sell
9,733
-11,182
-53% -$182K 0.01% 1056
2024
Q1 		$353K Buy
+20,915
New +$311K 0.02% 844
2023
Q4 		– Sell
-7,587
Closed -$78.1K – 1565
2023
Q3 		$78.1K Buy
+7,587
New +$102K 0.01% 1149
2022
Q4 		– Sell
-6,900
Closed -$34K – 1667
2022
Q3 		$34K Buy
+6,900
New +$38K ﹤0.01% 1298
2021
Q4 		– Sell
-5,800
Closed -$56K – 1493
2021
Q3 		$56K Buy
+5,800
New +$45.7K ﹤0.01% 1088
2021
Q1 		– Sell
-1,300
Closed -$8K – 1401
2020
Q4 		$8K Sell
1,300
-1,011
-44% -$6.32K ﹤0.01% 1118
2020
Q3 		$11K Buy
+2,311
New +$16.8K ﹤0.01% 1089

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Quantbot Technologies's AVDL Position: Q1 2026 in Review

Quantbot Technologies sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 79,909 shares — an estimated $1.72M sold.

Quantbot Technologies first reported a position in AVDL in Q3 2020 and held it in 9 quarters. The position peaked at $1.72M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Quantbot Technologies reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quantbot Technologies sold 79,909 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.72M.
  • Quantbot Technologies first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 9 quarters.
  • Quantbot Technologies's Avadel Pharmaceuticals position peaked at $1.72M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Quantbot Technologies's 13F filing for Q1 2026, filed 13 May 2026.